Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FKFU1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,901
Award facts
- Contract value 100% obligated
- $37,901.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $37,901.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on November 25, 2025, represents one of numerous orders placed under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The PPV-G GEN V is a comprehensive $30.3 billion acquisition strategy designed to establish regional prime vendor contractors capable of supplying a full range of pharmaceutical products to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's prime vendor contract, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, with a completion date of December 31, 2036, positioning the company as a critical supplier within the federal military medical supply chain.
The delivery order carries no set-aside designation, indicating DMS Pharmaceutical Group competed on an unrestricted basis and was selected based on competitive merit. XOLAIR, a biologic immunosuppressant agent, represents the type of specialty pharmaceutical product that DMS Pharmaceutical Group is authorized to supply under its prime vendor contract. The company's established distribution capabilities across diverse therapeutic categories, demonstrated through its substantial portfolio of oncology treatments, biologics, vaccines, and medical consumables, support its role as a comprehensive pharmaceutical supplier for the Department of Defense. The ultimate completion date for this delivery order is December 17, 2025.
Quick answers
Who was awarded contract SPE2DR26FKFU1?
SPE2DR26FKFU1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FKFU1 worth?
The government has obligated $37,901 on SPE2DR26FKFU1.
Is contract SPE2DR26FKFU1 an order under another contract?
Yes. SPE2DR26FKFU1 is a delivery order under SPE2DR25D9362, an indefinite delivery contract.
Was contract SPE2DR26FKFU1 competed?
The extent of competition for SPE2DR26FKFU1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award